|
Back to products
Browse products
Approved anticancer agents
Anticancer agents in trials
Anticancer agents
in preclinical trials
Anticancer molecular libraries
Other drug agents
Drug intermediates
Bio-reagents and biochemicals
|
MedKoo product information:
Elisidepsin
|
MedKoo Code#: 202300
|
|
Name: Elisidepsin
|
|
CAS#: 681272-30-0
Synonym:
Brand name: Irvalec®. PM02734
IUPAC/Chemical name:
(2R)-N-((S)-5-amino-1-(((2R,3S)-1-(((3S,9S,12S,15R,18S,19R,Z)-9-benzyl-15-((S)-sec-butyl)-6-ethylidene-3,12-diisopropyl-19-methyl-2,5,8,11,14,17-hexaoxo-1-oxa-4,7,10,13,16-pentaazacyclononadecan-18-yl)amino)-3-methyl-1-oxopentan-2-yl)amino)-1-oxopentan-2-yl)-1-((2R,5S,11R,16S)-8-((R)-1-hydroxyethyl)-2,5,11-triisopropyl-16-methyl-4,7,10,13-tetraoxo-3,6,9,12-tetraazaoctadecan-1-oyl)pyrrolidine-2-carboxamide
2,2,2-trifluoroacetate
|
|
Chemical structure:
|
|
|
|
Theoretical analysis:
|
PM02734
(trifluoroacetic acid, salt form)
Chemical Formula: C77H125F3N14O18
Molecular Weight: 1591.89
Elemental Analysis: C, 58.10; H, 7.91; F, 3.58; N, 12.32; O,
18.09
PM-02734 (free base form)
Chemical Formula: C75H124N14O16
Exact Mass: 1476.93197
Molecular Weight: 1477.87126
m/z: 1476.93197 (100.0%), 1477.93533 (81.1%), 1478.93868
(32.5%), 1479.94204 (8.5%), 1477.92901 (5.2%), 1478.93236
(4.2%), 1478.93622 (3.3%), 1479.93957 (2.7%), 1479.93572 (1.7%),
1480.94539 (1.7%), 1477.93825 (1.4%), 1478.94161 (1.2%),
1480.94293 (1.1%)
Elemental Analysis: C, 60.95; H, 8.46; N, 13.27; O, 17.32 |
|
Availability and price:
This agent is not in stock, which may be available through custom synthesis. To inquire quotation and lead time or to ask questions, please send email to
sales@medkoo.com to describe your needs. A representative
will respond your email shortly. We offer big discount for orders of bulk quantities.
|
|
Information about this agent
|
Elisidepsin is a
marine-derived, synthetic cyclic depsipeptide with potential
antineoplastic activity. Elisidepsin is a derivative of a natural marine
compound that belongs to a family of dehydro aminobutyric
acid-containing peptides (kahalalides) isolated from the herbivorous
marine mollusk Elysia rufescens. Although the primary mechanism of
action has yet to be elucidated, this agent exhibits anti-proliferative
activity in a wide variety of cancer cell types, including breast,
colon, pancreas, lung, and prostate; it appears to induce oncolytic
rather than apoptotic cell death. Check for
active clinical trials or
closed clinical trials using this agent. (NCI
Thesaurus)
Elisidepsin (PM02734) is a novel chemical entity
resulting from PharmaMar's internal research program for derivatives of
marine natural compounds. Produced synthetically in-house by PharmaMar,
PM02734 is a new depsipeptide of the kahalalides family. Preliminary in
vitro in-house studies identified PM02734 as a new antiproliferative
drug demonstrating activity against a broad spectrum of tumor types:
breast, colon, pancreas, lung and prostate, among others. PM02734 has
been selected for clinical development based on its in vivo activity in
xenografted human tumors, as well as an acceptable non-clinical
toxicology profile. The new Phase I clinical trial of PM02734 is a
multicenter, international (US and Europe) study designed to determine
safety and tolerability and to identify the maximum tolerated dose (MTD)
and recommended dose (RD) of PM02734 administered to patients with
advanced malignant solid tumors. (source:
prnewswire).
Current developer:
PharmaMar Inc
1: Provencio M, Sánchez A, Gasent J, Gómez P, Rosell
R. Cancer treatments: can we find treasures at the bottom of the sea?
Clin Lung Cancer. 2009 Jul;10(4):295-300. Review. PubMed PMID: 19632950.
2: Ling YH, Aracil M, Jimeno J, Perez-Soler R, Zou Y. Molecular
pharmacodynamics of PM02734 (elisidepsin) as single agent and in
combination with erlotinib; synergistic activity in human non-small cell
lung cancer cell lines and xenograft models. Eur J Cancer. 2009
Jul;45(10):1855-64. Epub 2009 Apr 5. PubMed PMID: 19346126; PubMed
Central PMCID: PMC2700178.
3: Herrero AB, Astudillo AM, Balboa MA, Cuevas C, Balsinde J, Moreno S.
Levels of SCS7/FA2H-mediated fatty acid 2-hydroxylation determine the
sensitivity of cells to antitumor PM02734. Cancer Res. 2008 Dec
1;68(23):9779-87. PubMed PMID: 19047157.
4: Yin J, Aviles P, Lee W, Ly C, Guillen MJ, Munt S, Cuevas C, Faircloth
G. Development of a liquid chromatography/tandem mass spectrometry assay
for the quantification of PM02734, a novel antineoplastic agent, in dog
plasma. Rapid Commun Mass Spectrom. 2006;20(18):2735-40. PubMed PMID:
16921565.
|
Contact MedKoo:
Email:
sales@medkoo.com
(Keyword; CAS#; MedKoo code#)
|
